QUARTERLY REPORT

Q1 2025 — Form 10-Q

Q1 2025PDF · 51 pages532 KB
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2025
OR
 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from 	to
Commission File No. 1-2189
ABBOTT LABORATORIES
An Illinois Corporation 	I.R.S. Employer Identification No.
36-0698440
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
Telephone: (224) 667-6100
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class 	Trading Symbol(s) 	Name of Each Exchange on Which Registered
Common Shares, Without Par Value 	ABT 	New York Stock Exchange
Chicago Stock Exchange, Inc.
Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes  No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes  No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an
emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth
company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer  	Accelerated Filer 
Non-Accelerated Filer  	Smaller reporting company 
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No 
As of March 31, 2025, Abbott Laboratories had 1,739,836,465 common shares without par value outstanding.

-- 1 of 51 --

Table of Contents
Abbott Laboratories
Table of Contents
Part I - Financial Information
Page
Item 1. Financial Statements and Supplementary Data
Condensed Consolidated Statement of Earnings 	3
Condensed Consolidated Statement of Comprehensive Income 	4
Condensed Consolidated Balance Sheet 	5
Condensed Consolidated Statement of Shareholders’ Investment 	6
Condensed Consolidated Statement of Cash Flows 	7
Notes to the Condensed Consolidated Financial Statements 	8
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 	21
Item 4. Controls and Procedures 	26
Part II - Other Information 	26
Item 1. Legal Proceedings 	26
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 	26
Item 6. Exhibits 	27
Signature 	28
2

-- 2 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited)
(dollars in millions except per share data; shares in thousands)
Three Months Ended
March 31
2025 	2024
Net sales 	$ 	10,358 $ 	9,964
Cost of products sold, excluding amortization of intangible assets 	4,468 	4,463
Amortization of intangible assets 	420 	472
Research and development 	716 	684
Selling, general and administrative 	3,061 	2,959
Total operating cost and expenses 	8,665 	8,578
Operating earnings 	1,693 	1,386
Interest expense 	131 	141
Interest (income) 	(82) 	(80)
Net foreign exchange (gain) loss 	(7) 	—
Other (income) expense, net 	(127) 	(111)
Earnings before taxes 	1,778 	1,436
Taxes on earnings 	453 	211
Net Earnings 	$ 	1,325 $ 	1,225
Basic Earnings Per Common Share 	$ 	0.76 $ 	0.70
Diluted Earnings Per Common Share 	$ 	0.76 $ 	0.70
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share 	1,739,206 	1,740,203
Dilutive Common Stock Options 	8,014 	9,449
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options 	1,747,220 	1,749,652
Outstanding Common Stock Options Having No Dilutive Effect 	1,431 	6,892
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
3

-- 3 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Comprehensive Income
(Unaudited)
(dollars in millions)
Three Months Ended
March 31
2025 	2024
Net Earnings 	$ 	1,325 $ 	1,225
Foreign currency translation gain (loss) adjustments, net of taxes of $32 in 2025 and $— in 2024 	550 	(386)
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $
— in 2025 and $1 in 2024 	30 	4
Net gains (losses) for derivative instruments designated as cash flow hedges, net of taxes of $(40) in 2025 and $30 in
2024 	(91) 	55
Other comprehensive income (loss) 	489 	(327)
Comprehensive Income 	$ 	1,814 $ 	898
March 31,
2025 December 31,
2024
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments 	$ 	(6,955) $ 	(7,505)
Net actuarial (losses) and prior service (costs) and credits 	(581) 	(611)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges 	119 	210
Accumulated other comprehensive income (loss) 	$ 	(7,417) $ 	(7,906)
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
4

-- 4 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Balance Sheet
(Unaudited)
(dollars in millions)
March 31,
2025
December 31,
2024
Assets
Current Assets:
Cash and cash equivalents 	$ 	6,532 $ 	7,616
Short-term investments 	312 	351
Trade receivables, less allowances of $449 in 2025 and $439 in 2024 	7,327 	6,925
Inventories:
Finished products 	4,063 	3,700
Work in process 	890 	840
Materials 	1,686 	1,654
Total inventories 	6,639 	6,194
Prepaid expenses and other receivables 	2,343 	2,570
Total Current Assets 	23,153 	23,656
Investments 	907 	886
Property and equipment, at cost 	23,418 	22,740
Less: accumulated depreciation and amortization 	12,486 	12,082
Net property and equipment 	10,932 	10,658
Intangible assets, net of amortization 	6,261 	6,647
Goodwill 	23,359 	23,108
Deferred income taxes and other assets 	16,836 	16,459
$ 	81,448 $ 	81,414
Liabilities and Shareholders’ Investment
Current Liabilities:
Trade accounts payable 	$ 	4,214 $ 	4,195
Salaries, wages and commissions 	1,167 	1,701
Other accrued liabilities 	5,600 	5,143
Dividends payable 	1,032 	1,024
Income taxes payable 	485 	594
Current portion of long-term debt 	506 	1,500
Total Current Liabilities 	13,004 	14,157
Long-term debt 	12,736 	12,625
Post-employment obligations, deferred income taxes and other long-term liabilities 	6,644 	6,731
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued 	— 	—
Common shares, without par value Authorized — 2,400,000,000 shares
Issued at stated capital amount — Shares: 2025: 1,995,858,606; 2024: 1,991,472,630 	25,125 	25,153
Common shares held in treasury, at cost — Shares: 2025: 256,021,416; 2024: 259,774,639 	(16,612) 	(16,844)
Earnings employed in the business 	47,715 	47,261
Accumulated other comprehensive income (loss) 	(7,417) 	(7,906)
Total Abbott Shareholders’ Investment 	48,811 	47,664
Noncontrolling Interests in Subsidiaries 	253 	237
Total Shareholders’ Investment 	49,064 	47,901
$ 	81,448 $ 	81,414
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
5

-- 5 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
Three Months Ended March 31
2025 	2024
Common Shares:
Balance at January 1
Shares: 2025: 1,991,472,630; 2024: 1,987,883,852 	$ 	25,153 $ 	24,869
Issued under incentive stock programs
Shares: 2025: 4,385,976; 2024: 1,906,147 	239 	87
Share-based compensation 	303 	322
Issuance of restricted stock awards 	(570) 	(552)
Balance at March 31
Shares: 2025: 1,995,858,606; 2024: 1,989,789,999 	$ 	25,125 $ 	24,726
Common Shares Held in Treasury:
Balance at January 1
Shares: 2025: 259,774,639; 2024: 253,807,494 	$ 	(16,844) $ 	(15,981)
Issued under incentive stock programs
Shares: 2025: 3,935,939; 2024: 3,838,255 	256 	242
Purchased
Shares: 2025: 182,716; 2024: 186,276 	(24) 	(22)
Balance at March 31
Shares: 2025: 256,021,416; 2024: 250,155,515 	$ 	(16,612) $ 	(15,761)
Earnings Employed in the Business:
Balance at January 1 	$ 	47,261 $ 	37,554
Net earnings 	1,325 	1,225
Cash dividends declared on common shares (per share — 2025: $0.59; 2024: $0.55) 	(1,033) 	(960)
Effect of common and treasury share transactions 	162 	192
Balance at March 31 	$ 	47,715 $ 	38,011
Accumulated Other Comprehensive Income (Loss):
Balance at January 1 	$ 	(7,906) $ 	(7,839)
Other comprehensive income (loss) 	489 	(327)
Balance at March 31 	$ 	(7,417) $ 	(8,166)
Noncontrolling Interests in Subsidiaries:
Balance at January 1 	$ 	237 $ 	224
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases 	16 	9
Balance at March 31 	$ 	253 $ 	233
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
6

-- 6 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Cash Flows
(Unaudited)
(dollars in millions)
Three Months Ended March 31
2025 	2024
Cash Flow From (Used in) Operating Activities:
Net earnings 	$ 	1,325 $ 	1,225
Adjustments to reconcile net earnings to net cash from operating activities —
Depreciation 	336 	333
Amortization of intangible assets 	420 	472
Share-based compensation 	289 	304
Trade receivables 	(262) 	(151)
Inventories 	(255) 	(410)
Other, net 	(436) 	(748)
Net Cash From Operating Activities 	1,417 	1,025
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment 	(484) 	(398)
Sales (purchases) of other investment securities, net 	8 	(28)
Other 	6 	1
Net Cash From (Used in) Investing Activities 	(470) 	(425)
Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other 	(36) 	(127)
Proceeds from issuance of long-term debt 	1 	—
Repayments of long-term debt 	(1,001) 	—
Purchases of common shares 	(280) 	(226)
Proceeds from stock options exercised 	287 	134
Dividends paid 	(1,026) 	(957)
Net Cash From (Used in) Financing Activities 	(2,055) 	(1,176)
Effect of exchange rate changes on cash and cash equivalents 	24 	(36)
Net Increase (Decrease) in Cash and Cash Equivalents 	(1,084) 	(612)
Cash and Cash Equivalents, Beginning of Year 	7,616 	6,896
Cash and Cash Equivalents, End of Period 	$ 	6,532 $ 	6,284
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
7

-- 7 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 1 — Basis of Presentation
The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and
Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However,
in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial
position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s
Annual Report on Form 10-K for the year ended December 31, 2024. The condensed consolidated financial statements include the accounts of the parent
company and subsidiaries, after elimination of intercompany transactions.
Note 2 — New Accounting Standards
Recently Adopted Accounting Standards
In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic
280): Improvements to Reportable Segment Disclosures, which expands the breadth and frequency of required segment disclosures. The guidance is
required to be applied retrospectively to all periods presented in the financial statements. Abbott adopted the standard on January 1, 2024. The new
standard did not have an impact on Abbott's consolidated financial statements, but required additional disclosures, retrospectively applied to all periods
presented in Note 14 — Segment and geographic area information.
Recent Accounting Standards Not Yet Adopted
In November 2024, the FASB issued ASU 2024-03, Income Statement (Subtopic 220-40): Reporting Comprehensive Income - Expense Disaggregation
Disclosures, which requires an entity to disclose on an annual and interim basis, disaggregated information about specific income statement expense
categories. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for Abbott
for full year 2027 reporting. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires an entity to
disclose annually additional information related to the company's income tax rate reconciliation and income taxes paid during the period. The guidance
should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for Abbott for full year 2025
reporting. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.
8

-- 8 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 3 — Revenue
Abbott’s revenues are derived primarily from the sale of a broad line of healthcare products under short-term receivable arrangements. Abbott has four
reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The following tables provide detail by sales category:
Three Months Ended March 31, 2025 	Three Months Ended March 31, 2024
(in millions) 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total
Established Pharmaceutical Products —
Key Emerging Markets 	$ 	— $ 	965 $ 	965 $ 	— $ 	928 $ 	928
Other 	— 	295 	295 	— 	298 	298
Total 	— 	1,260 	1,260 	— 	1,226 	1,226
Nutritional Products —
Pediatric Nutritionals 	588 	453 	1,041 	514 	495 	1,009
Adult Nutritionals 	367 	738 	1,105 	364 	695 	1,059
Total 	955 	1,191 	2,146 	878 	1,190 	2,068
Diagnostic Products —
Core Laboratory 	332 	845 	1,177 	310 	895 	1,205
Molecular 	40 	82 	122 	42 	87 	129
Point of Care 	100 	42 	142 	98 	41 	139
Rapid Diagnostics 	399 	214 	613 	481 	260 	741
Total 	871 	1,183 	2,054 	931 	1,283 	2,214
Medical Devices —
Rhythm Management 	304 	281 	585 	271 	291 	562
Electrophysiology 	299 	330 	629 	269 	318 	587
Heart Failure 	262 	77 	339 	237 	68 	305
Vascular 	268 	442 	710 	254 	435 	689
Structural Heart 	282 	295 	577 	233 	282 	515
Neuromodulation 	176 	52 	228 	181 	45 	226
Diabetes Care 	748 	1,079 	1,827 	589 	980 	1,569
Total 	2,339 	2,556 	4,895 	2,034 	2,419 	4,453
Other 	3 	— 	3 	3 	— 	3
Total 	$ 	4,168 $ 	6,190 $ 	10,358 $ 	3,846 $ 	6,118 $ 	9,964
Remaining Performance Obligations
As of March 31, 2025, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially
unsatisfied) was $5.7 billion in the Diagnostic Products segment and $423 million in the Medical Devices segment. Abbott expects to recognize revenue on
approximately 55 percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent 12 months
and the remainder thereafter.
9

-- 9 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 3 — Revenue (Continued)
These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended
warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has
applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance
obligations related to contracts with original expected durations of one year or less in the amounts above.
Other Contract Assets and Liabilities
Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets
primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and
the end of the period, as well as the changes in the balance, were not significant.
Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise
primarily in the Medical Devices segment when payment is received upfront for various multi-period extended service arrangements.
Changes in the contract liabilities during the period are as follows:
(in millions)
Contract Liabilities:
Balance at December 31, 2024 	$ 	568
Unearned revenue from cash received during the period 	132
Revenue recognized related to contract liability balance 	(99)
Balance at March 31, 2025 	$ 	601
Note 4 — Supplemental Financial Information
Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation
of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating
securities. Net earnings allocated to common shares for the three months ended March 31, 2025 and 2024 were $1.3 billion and $1.2 billion, respectively.
Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first three months of 2025 includes $235
million of pension contributions and the payment of cash taxes of $255 million. The first three months of 2024 included $280 million of pension
contributions and the payment of cash taxes of $225 million.
The following summarizes the activity for the first three months of 2025 related to the allowance for doubtful accounts as of March 31, 2025:
(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2024 	$ 	247
Provisions/charges to income 	23
Amounts charged off and other deductions 	(11)
Balance at March 31, 2025 	$ 	259
10

-- 10 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 4 — Supplemental Financial Information (Continued)
The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott
considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging
trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-
looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.
The components of long-term investments are as follows:
(in millions) March 31,
2025
December 31,
2024
Long-term Investments:
Equity securities 	$ 	572 $ 	553
Other 	335 	333
Total 	$ 	907 $ 	886
The increase in Abbott’s long-term investments as of March 31, 2025 versus the balance as of December 31, 2024 primarily relates to additional
investments, partially offset by the impairment of certain securities.
Abbott’s equity securities as of March 31, 2025 include $301 million of investments in mutual funds that are held in a rabbi trust. These investments, which
are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate
purposes and are subject to creditor claims in the event of insolvency.
Abbott also holds certain investments as of March 31, 2025 with a carrying value of $152 million that are accounted for under the equity method of
accounting and other equity investments with a carrying value of $109 million that do not have a readily determinable fair value.
Note 5 — Changes In Accumulated Other Comprehensive Income (Loss)
The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:
Three Months Ended March 31
Cumulative Foreign
Currency Translation
(Loss) Adjustments
Net Actuarial (Losses) and
Prior Service (Costs) and
Credits
Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges
(in millions) 	2025 	2024 	2025 	2024 	2025 	2024
Balance at January 1 	$ 	(7,505) $ 	(6,504) $ 	(611) $ 	(1,376) $ 	210 $ 	41
Other comprehensive income (loss) before
reclassifications 	550 	(386) 	30 	2 	(64) 	68
Amounts reclassified from accumulated
other comprehensive income 	— 	— 	— 	2 	(27) 	(13)
Net current period comprehensive income
(loss) 	550 	(386) 	30 	4 	(91) 	55
Balance at March 31 	$ 	(6,955) $ 	(6,890) $ 	(581) $ 	(1,372) $ 	119 $ 	96
Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of
net periodic benefit costs; see Note 12 — Post-Employment Benefits for additional details.
11

-- 11 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 6 — Goodwill and Intangible Assets
The total amount of goodwill reported was $23.4 billion at March 31, 2025 and $23.1 billion at December 31, 2024. The amount of goodwill related to
reportable segments at March 31, 2025 was $2.6 billion for the Established Pharmaceutical Products segment, $285 million for the Nutritional Products
segment, $3.5 billion for the Diagnostic Products segment, and $16.9 billion for the Medical Devices segment. Foreign currency translation adjustments
increased goodwill by $251 million in the first three months of 2025. There were no reductions of goodwill relating to impairments in the first three months
of 2025.
The gross amount of amortizable intangible assets, primarily product rights and technology, was $27.3 billion as of March 31, 2025 and $27.1 billion as of
December 31, 2024. Accumulated amortization was $21.8 billion and $21.3 billion as of March 31, 2025 and December 31, 2024, respectively. In the first
three months of 2025, intangible assets increased $34 million due to foreign currency translation. Abbott’s estimated annual amortization expense for
intangible assets is approximately $1.7 billion in 2025, $1.5 billion in 2026, $1.2 billion in 2027, $0.7 billion in 2028 and $0.6 billion in 2029.
Indefinite-lived intangible assets, which relate to in-process research and development (IPR&D) acquired in a business combination, were $784 million as
of March 31, 2025 and December 31, 2024.
Note 7 — Restructuring Plans
In 2025, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its diagnostic and medical
devices businesses. In the three months ended March 31, 2025, Abbott recorded employee related severance and other charges of $34 million, of which $13
million was recorded in Cost of products sold, $13 million was recorded in Research and development, and $8 million was recorded in Selling, general and
administrative expenses. Payments related to these actions totaled $4 million in the first three months of 2025 and the remaining liabilities totaled $30
million at March 31, 2025. In addition, Abbott recognized asset impairment charges of $12 million related to these restructuring plans.
In 2024 and 2023, Abbott management approved plans to restructure or streamline various operations in order to reduce costs in its medical devices,
diagnostic, nutritional and established pharmaceutical businesses, including the discontinuation of its ZonePerfect product line in 2024. In addition,
Abbott recognized asset impairment charges of approximately $30 million related to these restructuring plans in the first three months of 2024. The
following summarizes the activity related to these restructuring actions and the status of the related accruals as of March 31, 2025:
(in millions) 	Total
Accrued balance at December 31, 2024 	$ 	118
Payments and other adjustments 	(32)
Accrued balance at March 31, 2025 	$ 	86
®
12

-- 12 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 8 — Incentive Stock Programs
In the first three months of 2025, Abbott granted 1,426,812 stock options, 354,001 restricted stock awards and 4,240,698 restricted stock units under its
incentive stock program. At March 31, 2025, 50 million shares were reserved for future grants. Information regarding the number of options outstanding
and exercisable at March 31, 2025 is as follows:
Outstanding 	Exercisable
Number of shares 	23,554,185 	20,335,604
Weighted average remaining life (years) 	5.1 	4.4
Weighted average exercise price 	$ 	88.86 $ 	83.51
Aggregate intrinsic value (in millions) 	$ 	1,035 $ 	999
The total unrecognized share-based compensation cost at March 31, 2025 amounted to $790 million, which is expected to be recognized over the next three
years.
Note 9 — Debt and Lines of Credit
On March 17, 2025, Abbott repaid the $1.0 billion outstanding principal amount of its 2.95% Notes upon maturity.
Note 10 — Financial Instruments, Derivatives and Fair Value Measures
Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates,
primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross
notional amounts totaling $7.0 billion at March 31, 2025 and December 31, 2024, are designated as cash flow hedges of the variability of the cash flows
due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of March 31, 2025 will be included in Cost of
products sold at the time the products are sold, generally through the next twelve to eighteen months.
Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables
and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the
functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in
exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are
primarily the U.S. dollar and European currencies. At March 31, 2025 and December 31, 2024, Abbott held the gross notional amounts of $16.2 billion of
such foreign currency forward exchange contracts.
Abbott has designated a yen-denominated, 5-year term loan of $612 million and $583 million as of March 31, 2025 and December 31, 2024, respectively,
as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is
recorded in Accumulated other comprehensive income (loss), net of tax.
Abbott is a party to interest rate hedge contracts with a notional amount totaling $1.2 billion at March 31, 2025 and $2.2 billion at December 31, 2024 to
manage its exposure to changes in the fair value of fixed-rate debt. The decrease from December 31, 2024 was due to the maturity of $1.0 billion of interest
rate hedge contracts in conjunction with long-term debt, both of which matured in March 2025. These contracts are designated as fair value hedges of the
variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate
interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate
debt by an offsetting amount.
13

-- 13 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 10 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of March 31, 2025 and
December 31, 2024:
Fair Value - Assets 	Fair Value - Liabilities
(in millions) 	March 31, 2025 December 31, 2024 Balance Sheet Caption March 31, 2025 December 31, 2024 Balance Sheet Caption
Interest rate swaps designated as fair value
hedges:
Non-current 	$ 	— $ 	— Deferred income
taxes and other assets
$ 	48 $ 	51 Post-employment
obligations, deferred
income taxes and
other long-term
liabilities
Current 	— 	1 Prepaid expenses and
other receivables — 	— Other accrued
liabilities
Foreign currency forward exchange
contracts:
Hedging instruments 	82 	243 Prepaid expenses and
other receivables
75 	19 Other accrued
liabilities
Others not designated as hedges 	106 	147 Prepaid expenses and
other receivables
137 	112 Other accrued
liabilities
Debt designated as a hedge of net
investment in a foreign subsidiary
— 	— n/a 	612 	583 Long-term debt
$ 	188 $ 	391 	$ 	872 $ 	765
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative
financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income.
Gain (loss) Recognized in
Other
Comprehensive Income (loss)
Income (expense) and Gain
(loss)
Reclassified into Income
Three Months Ended March
31, Three Months Ended March
31,
(in millions) 	2025 	2024 	2025 	2024 Income Statement
Caption
Foreign currency forward exchange contracts designated as cash flow
hedges $ 	(94) $ 	127 $ 	39 $ 	18 Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary 	(29) 	24 	— 	— n/a
Interest rate swaps designated as fair value hedges 	n/a 	n/a 	3 	(24) Interest expense
Gains of $34 million and $92 million were recognized in the three months ended March 31, 2025 and 2024, respectively, related to foreign currency
forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net
foreign exchange (gain) loss line.
14

-- 14 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 10 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The carrying values and fair values of certain financial instruments as of March 31, 2025 and December 31, 2024 are shown in the following table. The
carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major
international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.
March 31, 2025 	December 31, 2024
(in millions) Carrying
Value
Fair
Value
Carrying
Value
Fair
Value
Long-term Investment Securities:
Equity securities 	$ 	572 $ 	572 $ 	553 $ 	553
Other 	335 	335 	333 	333
Total Long-term Debt 	(13,242) 	(12,975) 	(14,125) 	(13,710)
Foreign Currency Forward Exchange Contracts:
Receivable position 	188 	188 	390 	390
(Payable) position 	(212) 	(212) 	(131) 	(131)
Interest Rate Hedge Contracts:
Receivable position 	— 	— 	1 	1
(Payable) position 	(48) 	(48) 	(51) 	(51)
The fair value of the debt was determined based on significant other observable inputs, including current interest rates.
15

-- 15 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 10 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:
Basis of Fair Value Measurement
(in millions) Outstanding
Balances
Quoted
Prices in
Active
Markets
Significant
Other
Observable
Inputs
Significant
Unobservable
Inputs
March 31, 2025:
Equity securities 	$ 	311 $ 	311 $ 	— $ 	—
Foreign currency forward exchange contracts 	188 	— 	188 	—
Total Assets 	$ 	499 $ 	311 $ 	188 $ 	—
Fair value of hedged long-term debt 	$ 	1,112 $ 	— $ 	1,112 $ 	—
Interest rate swap derivative financial instruments 	48 	— 	48 	—
Foreign currency forward exchange contracts 	212 	— 	212 	—
Contingent consideration related to business combinations 	59 	— 	— 	59
Total Liabilities 	$ 	1,431 $ 	— $ 	1,372 $ 	59
December 31, 2024:
Equity securities 	$ 	323 $ 	323 $ 	— $ 	—
Interest rate swap derivative financial instruments 	1 	— 	1 	—
Foreign currency forward exchange contracts 	390 	— 	390 	—
Total Assets 	$ 	714 $ 	323 $ 	391 $ 	—
Fair value of hedged long-term debt 	$ 	2,096 $ 	— $ 	2,096 $ 	—
Interest rate swap derivative financial instruments 	51 	— 	51 	—
Foreign currency forward exchange contracts 	131 	— 	131 	—
Contingent consideration related to business combinations 	38 	— 	— 	38
Total Liabilities 	$ 	2,316 $ 	— $ 	2,278 $ 	38
The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative
instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based
on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on
independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value. The increase in the amount of
contingent consideration from December 31, 2024 reflects a fair value adjustment for contingent consideration related to a previous business combination.
The maximum amount for certain contingent consideration is not determinable as it is based on a percent of certain sales. Excluding such contingent
consideration, the maximum amount that may be due under the other contingent consideration arrangements was estimated at March 31, 2025 to be
$59 million, which is dependent upon attaining certain sales thresholds or upon the occurrence of certain events, such as regulatory approvals.
16

-- 16 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 11 — Litigation and Environmental Matters
Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto
Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded
an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is
expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.
Abbott has been named as a defendant in a number of lawsuits alleging that its preterm infant formula and human milk fortifier products that contain cow’s
milk cause an intestinal disease known as necrotizing enterocolitis (NEC) and inadequately warn about the risk of NEC. These lawsuits claim that certain
preterm infants suffered injury or death as a result of contracting NEC. In a trial held in July 2024, a jury in a Missouri state court awarded a plaintiff
$495 million in damages. Abbott stands by its products and the information it provided about them, and it appealed this jury’s verdict with the Missouri
Court of Appeals in December 2024. In a trial held in October 2024 involving Abbott and another infant formula manufacturer and the treating hospital as
co-defendants, a jury in a Missouri state court returned a unanimous verdict for Abbott and its co-defendants. In December 2024, the plaintiff filed a
motion for a new trial. In March 2025, the Missouri state court granted the plaintiff’s motion for a new trial, and Abbott appealed the ruling to the Missouri
Court of Appeals. Abbott does not believe that it is probable that a material loss will be incurred related to these lawsuits and therefore, no reserves have
been recorded. Given the uncertainty as to the possible outcome in each of these lawsuits, Abbott is unable to reasonably estimate a range of possible loss
related to these lawsuits.
Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental
exposures to be from approximately $25 million to $35 million. The recorded accrual balance at March 31, 2025 for these proceedings and exposures was
approximately $30 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.”
Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the
outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect
on Abbott’s financial position, cash flows, or results of operations, except for the cases discussed in the second paragraph of this note, the resolution of
which could be material to Abbott's financial position, cash flows or results of operations.
Note 12 — Post-Employment Benefits
Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are
recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net costs recognized for Abbott’s major defined
benefit plans and post-employment medical and dental benefit plans are as follows:
Defined Benefit Plans 	Medical and Dental Plans
Three Months Ended March 31, Three Months Ended March 31,
(in millions) 	2025 	2024 	2025 	2024
Service cost - benefits earned during the period 	$ 	54 $ 	61 $ 	10 $ 	10
Interest cost on projected benefit obligations 	122 	118 	16 	15
Expected return on plan assets 	(278) 	(262) 	(7) 	(6)
Net amortization of:
Actuarial loss, net 	2 	6 	— 	—
Prior service cost (credit) 	— 	— 	(2) 	(3)
Net cost (credit) 	$ 	(100) $ 	(77) $ 	17 $ 	16
17

-- 17 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 12 — Post-Employment Benefits (Continued)
Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded
according to similar regulations. In the first three months of 2025 and 2024, $235 million and $280 million, respectively, were contributed to defined
benefit plans. In the first three months of 2025 and 2024, $75 million and $28 million were contributed, respectively, to the post-employment medical and
dental plans.
Note 13 — Taxes on Earnings
Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first three months of 2025 and 2024,
taxes on earnings include $73 million and $25 million, respectively, in excess tax benefits associated with share-based compensation. The 2025 taxes on
earnings includes approximately $200 million of tax expense related to a deferred tax asset that was recognized as a significant non-cash tax benefit in a
prior year. In the first three months of 2024, taxes on earnings also included approximately $10 million of tax expense as the result of the resolution of
various tax positions related to prior years.
In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS) for the 2019 Federal tax year
in the amount of $417 million. The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its
foreign affiliates. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments
contradict methods that were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are
erroneous and unsupported. Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2023.
In June 2024, Abbott received a SNOD from the IRS for the 2017 and 2018 Federal tax years in the amount of $192 million. The matters proposed in the
2017/2018 SNOD are substantially similar to the income allocation adjustments included in the 2019 SNOD. Abbott filed a petition in September 2024
with the U.S. Tax Court contesting the 2017/2018 SNOD in a manner consistent with its petition for the 2019 SNOD.
In October 2024, Abbott received a SNOD from the IRS for the 2020 Federal tax year assessing an additional $443 million of income tax. The primary
adjustments proposed in the SNOD are substantially similar to the income allocation adjustments included in the 2017/2018 and 2019 SNODs. Abbott
believes that the income reallocation adjustments proposed in the SNOD are without merit. The SNOD also contains other proposed adjustments and
omissions that Abbott believes are erroneous and unsupported. In addition to the tax assessment for the 2020 tax year, the 2020 SNOD also contested a
deduction for which an estimated $440 million cash tax benefit would be available in a different taxable year as allowed under applicable U.S. tax law.
Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2024.
Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process and/or through
litigation as necessary. Abbott reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. Abbott continues
to believe that its reserves for uncertain tax positions are appropriate.
The Organization for Economic Cooperation & Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1
proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Abbott is continuing to analyze the Pillar
1 proposal. Pillar 2 proposes to assess a 15 percent minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis.
Numerous countries have enacted legislation to adopt the Pillar 2 model rules. The enactment of current Pillar 2 model rules did not and is not projected to
have a material impact to Abbott's consolidated financial statements.
18

-- 18 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 14 — Segment Information
Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of healthcare products. Abbott’s products are generally sold
directly to retailers, wholesalers, hospitals, healthcare facilities, laboratories, physicians’ offices and government agencies throughout the world.
Abbott’s reportable segments are as follows:
Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.
Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.
Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites.
For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics businesses are
aggregated and reported as the Diagnostic Products segment.
Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care
products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart,
Neuromodulation and Diabetes Care businesses are aggregated and reported as the Medical Devices segment.
Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are
on a performance basis consistent with internal management reporting. The chief operating decision maker (CODM) at Abbott is the Chief Executive
Officer (CEO). The CODM primarily considers sales and operating margin to assess the performance of segments and to allocate resources, where segment
operating margin profitability includes cost of products sold and operating expenses. The cost of some corporate functions and the cost of certain employee
benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible
asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.
19

-- 19 of 51 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 14 — Segment Information (Continued)
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not
presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.
Net Sales to External Customers 	Cost of Products Sold 	Research and Development
Selling, General and
Administrative 	Operating Earnings
For the three months ended March
31,
For the three months ended March
31,
For the three months ended March
31,
For the three months ended March
31,
For the three months ended March
31,
(in millions) 	2025 	2024 	2025 	2024 	2025 	2024 	2025 	2024 	2025 	2024
Established Pharmaceuticals 	$ 	1,260 $ 	1,226 $ 	(569) $ 	(584) $ 	(42) $ 	(41) $ 	(351) $ 	(334) $ 	298 $ 	267
Nutritionals 	2,146 	2,068 	(1,124) 	(1,088) 	(52) 	(52) 	(576) 	(551) 	394 	377
Diagnostics 	2,054 	2,214 	(1,152) 	(1,188) 	(151) 	(155) 	(392) 	(397) 	359 	474
Medical Devices 	4,895 	4,453 	(1,598) 	(1,547) 	(401) 	(368) 	(1,287) 	(1,178) 	1,609 	1,360
Total 	$ 	10,355 $ 	9,961 $ 	(4,443) $ 	(4,407) $ 	(646) $ 	(616) $ 	(2,606) $ 	(2,460) $ 	2,660 $ 	2,478
Other 	3 	3
Net sales 	$ 	10,358 $ 	9,964
Corporate functions and plan benefit costs 	(28) 	(66)
Net interest expense 	(49) 	(61)
Share-based compensation (a) 	(289) 	(304)
Amortization of Intangible assets 	(420) 	(472)
Other, net (b) 	(96) 	(139)
Earnings before Taxes 	$ 	1,778 $ 	1,436
______________________________________
(a) 	Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b) 	Other, net for the three months ended March 31, 2025 and 2024 includes charges related to restructurings, investment impairments, fair value adjustments to contingent
consideration and integration costs related to business combinations.
Depreciation
Additions to
Property and Equipment 	Total Assets
For the three months ended March 31, 	For the three months ended March 31, 	As of March 31, 	As of December 31,
(in millions) 	2025 	2024 	2025 	2024 	2025 	2024
Established Pharmaceuticals 	$ 	23 $ 	24 $ 	33 $ 	29 $ 	3,448 $ 	3,087
Nutritionals 	42 	39 	79 	73 	4,635 	4,404
Diagnostics 	126 	129 	135 	123 	7,840 	7,678
Medical Devices 	88 	87 	156 	135 	10,034 	9,472
Total Reportable Segments 	279 	279 	403 	360 $ 	25,957 $ 	24,641
Other 	57 	54 	60 	49
Total 	$ 	336 $ 	333 $ 	463 $ 	409
As of March 31, 	As of December 31,
(in millions) 	2025 	2024
Total Reportable Segment Assets 	$ 	25,957 $ 	24,641
Cash and investments 	7,751 	8,853
Goodwill and intangible assets 	29,620 	29,755
All other (c) 	18,120 	18,165
Total Assets 	$ 	81,448 $ 	81,414
(c) 	As of March 31, 2025 and December 31, 2024, all other includes the long-term assets associated with the defined benefit plans and certain deferred tax assets.
20

-- 20 of 51 --

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Financial Review — Results of Operations
Abbott’s revenues are derived primarily from the sale of a broad line of healthcare products under short-term receivable arrangements. Patent protection
and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most impact which products are sold; price
controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and
costs. Abbott’s primary products are medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals.
The following tables detail sales by reportable segment for the three months ended March 31. Percent changes are versus the prior year and are based on
unrounded numbers.
Net Sales to External Customers
(in millions)
Three Months
Ended
March 31, 2025
Three Months
Ended
March 31, 2024
Total
Change
Impact of
Foreign
Exchange
Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products 	$ 	1,260 $ 	1,226 	2.7 % 	(5.1)% 	7.8 %
Nutritional Products 	2,146 	2,068 	3.8 	(2.4) 	6.2
Diagnostic Products 	2,054 	2,214 	(7.2) 	(2.3) 	(4.9)
Medical Devices 	4,895 	4,453 	9.9 	(2.7) 	12.6
Total Reportable Segments 	10,355 	9,961 	4.0 	(2.8) 	6.8
Other 	3 	3 	n/m 	n/m 	n/m
Net Sales 	$ 	10,358 $ 	9,964 	4.0 	(2.8) 	6.8
Total U.S. 	$ 	4,168 $ 	3,846 	8.4 	— 	8.4
Total International 	$ 	6,190 $ 	6,118 	1.2 	(4.5) 	5.7
____________________________________
Notes: 	In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year
average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
n/m = Percent change is not meaningful
21

-- 21 of 51 --

Table of Contents
The 6.8 percent increase in total net sales during the first quarter of 2025, excluding the impact of foreign exchange, primarily reflected higher sales in the
Medical Devices, Established Pharmaceutical Products and Nutritional Products segments, fueled by higher sales of existing products as well as the
introduction of new products. Diagnostic Products sales growth continued to be impacted by the decline in COVID-19 testing-related sales and the impact
of volume-based procurement programs in China. COVID-19 testing-related sales were $84 million in the first quarter of 2025 compared to $204 million in
the first quarter of 2024. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the first quarter as the relatively stronger
U.S. dollar decreased total international sales by 4.5 percent and total sales by 2.8 percent.
The table below provides detail by sales category for the three months ended March 31. Percent changes are versus the prior year and are based on
unrounded numbers.
(in millions) 	March 31, 2025 	March 31, 2024
Total
Change
Impact of
Foreign
Exchange
Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products —
Key Emerging Markets 	$ 	965 $ 	928 	4.0 % 	(5.3)% 	9.3 %
Other Emerging Markets 	295 	298 	(1.2) 	(4.3) 	3.1
Nutritional Products —
International Pediatric Nutritionals 	453 	495 	(8.4) 	(3.6) 	(4.8)
U.S. Pediatric Nutritionals 	588 	514 	14.2 	— 	14.2
International Adult Nutritionals 	738 	695 	6.1 	(4.5) 	10.6
U.S. Adult Nutritionals 	367 	364 	1.1 	— 	1.1
Diagnostic Products —
Core Laboratory 	1,177 	1,205 	(2.3) 	(3.2) 	0.9
Molecular 	122 	129 	(5.9) 	(2.4) 	(3.5)
Point of Care 	142 	139 	2.4 	(0.8) 	3.2
Rapid Diagnostics 	613 	741 	(17.3) 	(1.2) 	(16.1)
Medical Devices —
Rhythm Management 	585 	562 	4.0 	(2.1) 	6.1
Electrophysiology 	629 	587 	7.3 	(2.6) 	9.9
Heart Failure 	339 	305 	11.4 	(1.0) 	12.4
Vascular 	710 	689 	3.0 	(2.7) 	5.7
Structural Heart 	577 	515 	11.9 	(2.8) 	14.7
Neuromodulation 	228 	226 	1.0 	(1.2) 	2.2
Diabetes Care 	1,827 	1,569 	16.5 	(3.3) 	19.8
22

-- 22 of 51 --

Table of Contents
In the first three months of 2025, total Established Pharmaceutical Products sales, excluding the impact of foreign exchange, increased 7.8 percent.
Excluding the unfavorable effect of foreign exchange, sales in Key Emerging Markets for Established Pharmaceutical Products increased 9.3 percent in the
first three months of 2025, led by higher revenue in several countries and across several therapeutic areas, including cardiometabolic, gastroenterology,
central nervous system/pain management and respiratory. Other Emerging Markets, excluding the effect of foreign exchange, increased by 3.1 percent in
the first three months of 2025.
Excluding the impact of foreign exchange, total Nutritional Products sales in the first three months of 2025 increased 6.2 percent. In U.S. Pediatric
Nutritionals, the 14.2 percent increase in sales in the first three months of 2025 reflects sales growth across the product portfolio. Excluding the effect of
foreign exchange, the 4.8 percent decrease in International Pediatric Nutritionals sales in the first three months of 2025 reflects a decrease in sales in the
Asia Pacific and Latin America regions, partially offset by increased sales in Canada and the Europe/Middle East regions.
In the first three months of 2025, U.S. and International Adult Nutritionals sales, excluding the effect of foreign exchange, increased 1.1 percent and 10.6
percent, respectively, due to growth of Ensure and Glucerna product sales. U.S. Adult Nutritionals sales were partially offset by the discontinuation of
the ZonePerfect product line in March 2024.
Diagnostic Products sales decreased 4.9 percent in the first three months of 2025, excluding the impact of foreign exchange. In Core Laboratory, sales
increased 0.9 percent in the first three months of 2025, excluding the effect of foreign exchange, due to continued deployment of Abbott's Alinity testing
platform, mostly offset by the impact of volume-based procurement programs in China. In Rapid Diagnostics, sales decreased 16.1 percent in the first three
months of 2025, excluding the effect of foreign exchange, primarily due to lower demand for COVID-19 tests.
Excluding the effect of foreign exchange, total Medical Devices sales increased 12.6 percent in the first three months of 2025, led by growth in Diabetes
Care, Structural Heart, Heart Failure and Electrophysiology. Higher Diabetes Care sales were driven by continued growth in Abbott's continuous glucose
monitoring (CGM) systems. CGM systems sales totaled $1.7 billion and $1.5 billion in the first three months of 2025 and 2024, respectively. Excluding the
effect of foreign exchange, CGM systems sales increased 21.6 percent in the first three months of 2025.
During the first three months of 2025, procedure volumes continued to increase across the cardiovascular and neuromodulation businesses. In Structural
Heart, the 14.7 percent increase in sales, excluding the effect of foreign exchange, primarily reflects growth in Navitor and TriClip products. In Heart
Failure, the 12.4 percent increase in sales, excluding the effect of foreign exchange, primarily reflects growth in chronic and acute pump products and
related accessories. In Electrophysiology, the 9.9 percent increase in sales, excluding the effect of foreign exchange, primarily reflects higher procedure
volumes and increased demand for diagnostic and mapping catheters.
In Rhythm Management, the 6.1 percent sales increase in the first three months of 2025, excluding the impact of foreign exchange, was primarily due to
growth in Aveir leadless pacemakers, partially offset by a decrease in traditional pacemaker and implantable cardioverter-defibrillator sales. In Vascular,
the 5.7 percent increase in sales, excluding the impact of foreign exchange, was primarily due to growth in vascular imaging, vessel closure products and
the Esprit™ (BTK) system, Abbott's below-the-knee resorbable stent.
In March 2025, Abbott obtained CE Mark for its Volt™ Pulse Field Ablation (PFA) System to treat patients with atrial fibrillation.
The gross profit margin percentage was 52.8 percent for the first quarter of 2025 compared to 50.5 percent for the first quarter of 2024. The increase in the
first three months of 2025 reflects the favorable impacts of gross margin improvement initiatives and foreign exchange.
Research and development (R&D) expenses increased $32 million to $716 million, or 4.6 percent, in the first quarter of 2025. The increase in R&D
expense in the first three months of 2025 was primarily driven by higher spending on various projects.
Selling, general and administrative expenses increased $102 million, or 3.5 percent, in the first quarter of 2025 as higher selling and marketing spending to
drive growth across various businesses was partially offset by the favorable impact of foreign exchange.
® 	®
®
®
® 	®
®
23

-- 23 of 51 --

Table of Contents
Restructuring Plans
In 2025, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its diagnostic and medical
devices businesses. In the three months ended March 31, 2025, Abbott recorded employee related severance and other charges of $34 million, of which $13
million was recorded in Cost of products sold, $13 million was recorded in Research and development, and $8 million was recorded in Selling, general and
administrative expenses. Payments related to these actions totaled $4 million in the first three months of 2025 and the remaining liabilities totaled $30
million at March 31, 2025. In addition, Abbott recognized asset impairment charges of $12 million related to these restructuring plans.
Other (Income) Expense, net
Other income, net increased from $111 million of income in the first quarter of 2024 to $127 million of income in the first quarter of 2025. The increase in
the first three months of 2025 primarily reflects lower investment impairments and higher income associated with the non-service cost components of net
pension and post-retirement medical benefit costs, partially offset by unfavorable changes in the fair value of contingent consideration liabilities related to
previous business combinations.
Interest Expense, net
Interest expense, net decreased $12 million to $49 million in the first quarter of 2025. In the first quarter of 2025, interest expense decreased primarily as a
result of the repayment of long-term debt in November of 2024 and March 2025, combined with an increase in interest income due to higher average cash
and short-term investment balances versus the prior year.
Taxes on Earnings
Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first three months of 2025 and 2024,
taxes on earnings include $73 million and $25 million, respectively, in excess tax benefits associated with share-based compensation. The 2025 taxes on
earnings includes approximately $200 million of tax expense related to a deferred tax asset that was recognized as a significant non-cash tax benefit in a
prior year. In the first three months of 2024, taxes on earnings also included approximately $10 million of tax expense as the result of the resolution of
various tax positions related to prior years.
In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS) for the 2019 Federal tax year
in the amount of $417 million. The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its
foreign affiliates. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments
contradict methods that were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are
erroneous and unsupported. Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2023.
In June 2024, Abbott received a SNOD from the IRS for the 2017 and 2018 Federal tax years in the amount of $192 million. The matters proposed in the
2017/2018 SNOD are substantially similar to the income allocation adjustments included in the 2019 SNOD. Abbott filed a petition in September 2024
with the U.S. Tax Court contesting the 2017/2018 SNOD in a manner consistent with its petition for the 2019 SNOD.
In October 2024, Abbott received a SNOD from the IRS for the 2020 Federal tax year assessing an additional $443 million of income tax. The primary
adjustments proposed in the SNOD are substantially similar to the income allocation adjustments included in the 2017/2018 and 2019 SNODs. Abbott
believes that the income reallocation adjustments proposed in the SNOD are without merit. The SNOD also contains other proposed adjustments and
omissions that Abbott believes are erroneous and unsupported. In addition to the tax assessment for the 2020 tax year, the 2020 SNOD also contested a
deduction for which an estimated $440 million cash tax benefit would be available in a different taxable year as allowed under applicable U.S. tax law.
Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2024.
24

-- 24 of 51 --

Table of Contents
Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process and/or through
litigation as necessary. Abbott reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. Abbott continues
to believe that its reserves for uncertain tax positions are appropriate.
The Organization for Economic Cooperation & Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1
proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Abbott is continuing to analyze the Pillar
1 proposal. Pillar 2 proposes to assess a 15 percent minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis.
Numerous countries have enacted legislation to adopt the Pillar 2 model rules. The enactment of current Pillar 2 model rules did not and is not projected to
have a material impact to Abbott's consolidated financial statements.
Liquidity and Capital Resources
The decrease in cash and cash equivalents from $7.6 billion at December 31, 2024 to $6.5 billion at March 31, 2025 reflects the repayment of debt in
March 2025 of $1.0 billion, the payment of dividends and capital expenditures in the first three months of 2025, partially offset by cash generated from
operations. Working capital was $10.1 billion at March 31, 2025 and $9.5 billion at December 31, 2024. The increase in working capital in 2025 primarily
reflects increases in inventory and trade receivables.
In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first three months of 2025 totaled $1.4 billion, an
increase of $392 million from the prior year, primarily due to higher segment operating earnings. In the first three months of 2025, Net cash from operating
activities included $235 million of pension contributions and the payment of cash taxes of $255 million. Net cash from operating activities in 2024
included $280 million of pension contributions and the payment of cash taxes of $225 million.
At March 31, 2025, Abbott’s long-term debt rating was AA- by S&P Global Ratings and Aa3 by Moody’s Investors Service. Abbott expects to maintain an
investment grade rating.
On March 17, 2025, Abbott repaid the $1.0 billion outstanding principal amount of its 2.95% Notes upon maturity.
In October 2024, the board of directors authorized the repurchase of up to $7 billion of Abbott common shares, from time to time. The new authorization is
in addition to the $293 million unused portion of the share repurchase program authorized in December 2021.
In the first quarter of 2025, Abbott declared a quarterly dividend of $0.59 per share on its common shares, which represents an increase of 7.3 percent over
the $0.55 per share dividend declared in the first quarter of 2024.
Legislative Issues
Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue
over the availability, method of delivery, and payment for healthcare products and services. It is not possible to predict the extent to which Abbott or the
healthcare industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1,
Business, and Item 1A, Risk Factors, in the 2024 Annual Report on Form 10-K.
Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements
Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions that any forward-looking statements made by
Abbott are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.
Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our
Annual Report on Form 10-K for the year ended December 31, 2024, and are incorporated herein by reference. Abbott undertakes no obligation to release
publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
25

-- 25 of 51 --

Table of Contents
PART I. FINANCIAL INFORMATION
Item 4. Controls and Procedures
(a) Evaluation of disclosure controls and procedures. The Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, Philip P. Boudreau,
evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and
concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose
in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of
1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and
forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is
accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate
to allow timely decisions regarding required disclosure.
(b) Changes in internal control over financial reporting. During the quarter ended March 31, 2025, there were no changes in Abbott’s internal
control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to
materially affect, Abbott’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
Abbott is involved in various claims, legal proceedings and investigations as described in its Annual Report on Form 10-K for the year ended December
31, 2024 (the “2024 10-K”), including those described below (as of March 31, 2025, except where noted below). While it is not feasible to predict the
outcome of such pending claims, proceedings, and investigations with certainty, management is of the opinion that their ultimate resolution should not have
a material adverse effect on Abbott's financial position, cash flows, or results of operations.
In the 2024 10-K, Abbott reported that it is a defendant in numerous lawsuits alleging that preterm infants developed necrotizing enterocolitis as a result of
being administered Abbott’s preterm infant formula products. Abbott further reported in the 2024 10-K that in a trial held in October 2024 involving
Abbott and another infant formula manufacturer and the treating hospital as co-defendants, a jury in a Missouri state court returned a unanimous verdict for
Abbott and its co-defendants and that in December 2024, the plaintiff filed a motion for a new trial. In March 2025, the Missouri state court granted the
plaintiff’s motion for a new trial, and Abbott appealed the ruling to the Missouri Court of Appeals.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(c) Issuer Purchases of Equity Securities
Period
(a) Total
Number of
Shares (or
Units)
Purchased
(b) Average
Price Paid per
Share (or
Unit)
(c) Total Number
of Shares (or
Units) Purchased
as Part of
Publicly
Announced Plans
or Programs
(d) Maximum
Number (or
Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs
January 1, 2025 - January 31, 2025 	— 	$ 	— 	— $ 	7,293,222,352
February 1, 2025 - February 28, 2025 	— 	— 	— 	7,293,222,352
March 1, 2025 - March 31, 2025 	— 	— 	— 	7,293,222,352
Total 	— 	$ 	— 	— $ 	7,293,222,352
______________________________________
1. These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.
2. On December 10, 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time (the "2021 Plan"). On October 11, 2024, the board
of directors authorized the repurchase of up to $7 billion of Abbott common shares, from time to time (the "2024 Plan"). The 2024 Plan is in addition to the unused portion of the 2021 Plan.
(1) 	(2)
(1) 	(2)
(1) 	(2)
(1) 	(2)
26

-- 26 of 51 --

Table of Contents
Item 6. Exhibits
Exhibit No. 	Exhibit
10.1 	Abbott Laboratories Non-Employee Directors' Fee Plan, as amended and restated.
31.1 	Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
31.2 	Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.
32.1 	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002.
32.2 	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002.
101 	The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter ended
March 31, 2025, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated
Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of
Shareholders’ Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed Consolidated
Financial Statements.
104 	Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit
101).
27

-- 27 of 51 --

Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ABBOTT LABORATORIES
By: 	/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Executive Vice President, Finance
and Chief Financial Officer
Date: April 30, 2025
28

-- 28 of 51 --

Exhibit 10.1
As Amended and Restated
effective May 1, 2025
ABBOTT LABORATORIES NON-EMPLOYEE DIRECTORS’ FEE PLAN
SECTION 1.
PURPOSE
ABBOTT LABORATORIES NON-EMPLOYEE DIRECTORS’ FEE PLAN - referred to below as the “Plan” - has been established
by ABBOTT LABORATORIES - referred to below as the “Company” - to attract and retain as members of its Board of Directors persons
who are not full-time employees of the Company or any of its subsidiaries but whose business experience and judgment are a valuable asset
to the Company and its subsidiaries.
SECTION 2.
DIRECTORS COVERED
As used in the Plan, the term “Director” means any person who is elected to the Board of Directors of the Company in April, 1962 or
at any time thereafter, and is not a full-time employee of the Company or any of its subsidiaries.
SECTION 3.
FEES PAYABLE TO DIRECTORS
3.1 	Each Director shall be entitled to a deferred monthly fee of Ten Thousand Five Hundred Dollars ($10,500.00) for each
calendar month or portion thereof (excluding the month in which he is first elected a Director) that he holds such office with the Company.
3.2 	A Director who serves as Chairman of the Executive Committee of the Board of Directors shall be entitled to a deferred
monthly fee of One Thousand Six Hundred Dollars ($1,600.00) for each calendar month or portion thereof (excluding the month in which he
is first elected to such position) that he holds such position.
3.3 	A Director who serves as Lead Director of the Board of Directors shall be entitled to a deferred monthly fee of Three
Thousand Three Hundred Thirty-Three Dollars and Thirty-Three Cents ($3,333.33) for each calendar month or portion thereof (excluding the
month in which he is first elected to such position) that he holds such position. The Lead Director shall not be entitled to any fees under
Section 3.6.
3.4 	Audit Committee Fees
(a) 	A Director who serves as Chairman of the Audit Committee of the Board of Directors shall be entitled to a deferred
monthly fee of Two Thousand Five Hundred Dollars ($2,500.00) for each calendar month or portion thereof
(excluding the month in which he is first elected to such position) that he holds such position.

-- 29 of 51 --

(b) 	Each Director who serves on the Audit Committee of the Board of Directors (other than the Chairman of the Audit
Committee) shall be entitled to a deferred monthly fee of Five Hundred Dollars ($500.00) for each calendar month
or portion thereof (excluding the month in which he is first elected to such position) that he holds such position.
3.5 	A Director who serves as Chairman of the Compensation Committee of the Board of Directors shall be entitled to a deferred
monthly fee of Two Thousand Eighty-Three Dollars and Thirty-Three Cents ($2,083.33) for each calendar month or portion thereof
(excluding the month in which he is first elected to such position) that he holds such position.
3.6 	Except as provided in Section 3.3, a Director who serves as Chairman of the Nominations and Governance Committee of the
Board of Directors shall be entitled to a deferred monthly fee of Two Thousand Eighty-Three Dollars and Thirty-Three Cents ($2,083.33) for
each calendar month or portion thereof (excluding the month in which he is first elected to such position) that he holds such position.
3.7 	A Director who serves as Chairman of the Public Policy Committee of the Board of Directors shall be entitled to a deferred
monthly fee of Two Thousand Eighty-Three Dollars and Thirty-Three Cents ($2,083.33) for each calendar month or portion thereof
(excluding the month in which he is first elected to such position) that he holds such position.
3.8 	A Director who serves as Chairman of any other Committee created by this Board of Directors shall be entitled to a deferred
monthly fee of One Thousand Two Hundred Fifty Dollars ($1,250.00) for each calendar month or portion thereof (excluding the month in
which he is first elected to such position) that he holds such position.
3.9 	A Director’s Deferred Fee Account shall be credited with interest annually. During the calendar years 1968 and prior, the rate
of interest credited to deferred fees shall be four (4) percent per annum. During the calendar years 1969 through 1992, the rate of interest
credited to deferred fees shall be the average of the prime rates being charged by the two largest commercial banks in the City of Chicago as
of the end of the month coincident with or last preceding the date upon which said interest is so credited. During the calendar years 1993
through 2007, the rate of interest credited to deferred fees shall be equal to: (a) the average of the prime rates being charged by the two
largest commercial banks in the City of Chicago as of the end of the month coincident with or last preceding the date upon which said
interest is so credited; plus (b) two hundred twenty-five (225) basis points. For the calendar year 2008 and subsequent years, the rate of
interest credited to deferred fees shall be equal to: (a) the average of the “prime rate” of interest published by The Wall Street Journal (Mid-
West Edition) or comparable successor quotation service on the first business day of January and the last business day of each month of the
fiscal year; plus (b) two hundred twenty-five (225) basis points. For purposes of this provision, the term “deferred fees” shall include
“deferred monthly fees,” and “deferred meeting fees,” and shall also include any such interest credited thereon.
3.10 	For purposes of Sections 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, and 3.8, the automatic deferral of the fees specified therein shall be
subject to a Director’s election to receive such fees currently pursuant to Section 4.1 or Section 8.1 of the Plan.
SECTION 4.
PAYMENT OF DIRECTORS’ FEES
4.1 	Any Director may, by written notice filed with the Secretary of the Company no later than December 31 in a calendar year,
elect to receive current payment of all or any portion of the monthly and meeting fees earned by him in calendar years subsequent to the
calendar year in which he files such notice, in which case such fees shall not be deferred but shall be paid quarterly as earned and no interest
shall be credited thereon. Such election shall be irrevocable as of December 31 of the year prior to the year in which the fees will be earned.
Notwithstanding the timing requirements described above, an individual who is newly elected as a Director may make the election described
above by filing it with the Secretary of the Company within the thirty (30) day period immediately following the date he or she first becomes
a Director eligible to participate in the Plan (and all plans that would be aggregated with the Plan
2

-- 30 of 51 --

pursuant to Treasury Regulation §1.409A-1(c)(2)(i)), provided, that the compensation subject to such election relates solely to services
performed after the date of such election and provided further, that such election shall become irrevocable on the thirtieth day following the
date he or she first becomes a Director eligible to participate in the Plan. In no event shall the fees subject to an election under this Section
4.1 be paid later than the last day of the “applicable 2½ month period”, as such term is defined in Treasury Regulation § 1.409A-1(b)(4)(i)
(A). Any Director who has previously provided notice pursuant to this Section 4.1 may, by written notice filed with the Secretary of the
Company no later than December 31 in a calendar year, elect to defer payment of all or a portion of the monthly and meeting fees earned by
him in calendar years subsequent to the year in which he files such notice, in which case such fees shall be paid to him in accordance with
Section 4.2 below.
4.2 	A Director’s deferred fees earned pursuant to the Plan shall commence to be paid on the first day of the calendar month next
following the earlier of his death or his attainment of age sixty-five (65) if he is not then serving as a Director, or the termination of his
service as a Director if he serves as a Director after the attainment of age sixty-five (65).
4.3 	A Director’s deferred fees that have commenced to be payable pursuant to Section 4.2 shall be payable in annual installments
in the order in which they shall have been deferred (i.e., the deferred fees and earnings thereon for the earliest year of service as a Director
will be paid on the date provided for in Section 4.2, the deferred fees for the next earliest year of service as a Director will be paid on the
anniversary of the payment of the first installment, etc.).
4.4 	A Director’s deferred fees shall continue to be paid until all deferred fees which he is entitled to receive under the Plan shall
have been paid to him (or, in case of his death, to his beneficiary).
4.5 	If a Director incurs a termination of service as a Director within two (2) years following the occurrence of a Change in
Control (as defined below), the aggregate unpaid balance of such Director’s deferred fees plus all unpaid interest credited thereon, shall be
paid to such Director in a lump sum within thirty (30) days following the date of such termination of service; provided, however, that if such
Change in Control does not constitute a “change in control event” (as defined in Treasury Regulation § 1.409A-3(i)(5)), then the aggregate
unpaid balance of such Director’s deferred fees shall be paid in accordance with Sections 4.2 and 4.3.
Notwithstanding any other provision of the Plan, if a Director has made the alternative election set forth in Section 8.1, and if such Director
incurs a termination of service as a Director within five (5) years following the occurrence of a Change in Control, the aggregate unpaid
balance of such Director’s fees deposited to the Director’s Grantor Trust (as defined below) plus all unpaid interest credited thereon, shall be
paid to such Director from the Director’s Grantor Trust in a lump sum within thirty (30) days following the date of such termination of
service.
4.6 	A “Change in Control” shall be deemed to have occurred on the earliest of the following dates:
(i) 	the date any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company
(not including in the securities beneficially owned by such Person any securities acquired directly from the
Company or its Affiliates) representing 20% or more of the combined voting power of the Company’s then
outstanding securities, excluding any Person who becomes such a Beneficial Owner in connection with a
transaction described in clause (a) of paragraph (iii) below; or
(ii) 	the date the following individuals cease for any reason to constitute a majority of the number of directors
then serving: individuals who, on the date hereof, constitute the Board of Directors and any new director
(other than a director whose initial assumption of office is in connection with an actual or threatened election
contest, including but not limited to
3

-- 31 of 51 --

a consent solicitation, relating to the election of directors of the Company) whose appointment or election by
the Board of Directors or nomination for election by the Company’s shareholders was approved or
recommended by a vote of at least two-thirds (2/3) of the directors then still in office who either were
directors on the date hereof or whose appointment, election or nomination for election was previously so
approved or recommended; or
(iii) 	the date on which there is consummated a merger or consolidation of the Company or any direct or indirect
subsidiary of the Company with any other corporation or other entity, other than (a) a merger or
consolidation (I) immediately following which the individuals who comprise the Board of Directors
immediately prior thereto constitute at least a majority of the Board of Directors of the Company, the entity
surviving such merger or consolidation or, if the Company or the entity surviving such merger or
consolidation is then a subsidiary, the ultimate parent thereof and (II) which results in the voting securities of
the Company outstanding immediately prior to such merger or consolidation continuing to represent (either
by remaining outstanding or by being converted into voting securities of the surviving entity or any parent
thereof), in combination with the ownership of any trustee or other fiduciary holding securities under an
employee benefit plan of the Company or any subsidiary of the Company, at least 50% of the combined
voting power of the securities of the Company or such surviving entity or any parent thereof outstanding
immediately after such merger or consolidation, or (b) a merger or consolidation effected to implement a
recapitalization of the Company (or similar transaction) in which no Person is or becomes the Beneficial
Owner, directly or indirectly, of securities of the Company (not including in the securities Beneficially
Owned by such Person any securities acquired directly from the Company or its Affiliates) representing 20%
or more of the combined voting power of the Company’s then outstanding securities; or
(iv) 	the date the shareholders of the Company approve a plan of complete liquidation or dissolution of the
Company or there is consummated an agreement for the sale or disposition by the Company of all or
substantially all of the Company’s assets, other than a sale or disposition by the Company of all or
substantially all of the Company’s assets to an entity, at least 50% of the combined voting power of the
voting securities of which are owned by shareholders of the Company, in combination with the ownership of
any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any
subsidiary of the Company, in substantially the same proportions as their ownership of the Company
immediately prior to such sale.
(1) Notwithstanding the foregoing, a “Change in Control” shall not be deemed to have occurred by virtue of
the consummation of any transaction or series of integrated transactions immediately following
which the record holders of the common stock of the Company immediately prior to such
transaction or series of transactions continue to have substantially the same proportionate ownership
in an entity which owns all or substantially all of the assets of the Company immediately following
such transaction or series of transactions.
(2) For purposes of this Plan: “Affiliate” shall have the meaning set forth in Rule 12b-2 promulgated under
Section 12 of the
4

-- 32 of 51 --

Exchange Act; “Beneficial Owner” shall have the meaning set forth in Rule 13d-3 under the
Exchange Act; “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from
time to time; and “Person” shall have the meaning given in Section 3(a)(9) of the Exchange Act, as
modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (i) the
Company or any of its subsidiaries, (ii) a trustee or other fiduciary holding securities under an
employee benefit plan of the Company or any of its Affiliates, (iii) an underwriter temporarily
holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or
indirectly, by the shareholders of the Company in substantially the same proportions as their
ownership of stock of the Company.
4.7 	A “Potential Change in Control” shall exist during any period in which the circumstances described in paragraphs (i), (ii),
(iii) or (iv), below, exist (provided, however, that a Potential Change in Control shall cease to exist not later than the occurrence of a Change
in Control):
(i) 	The Company enters into an agreement, the consummation of which would result in the occurrence of a
Change in Control, provided that a Potential Change in Control described in this paragraph (i) shall cease to
exist upon the expiration or other termination of all such agreements.
(ii) 	Any Person (without regard to the exclusions set forth in subsections (i) through (iv) of such definition)
publicly announces an intention to take or to consider taking actions the consummation of which would
constitute a Change in Control; provided that a Potential Change in Control described in this paragraph (ii)
shall cease to exist upon the withdrawal of such intention, or upon a determination by the Board of Directors
that there is no reasonable chance that such actions would be consummated.
(iii) 	Any Person becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing
10% or more of either the then outstanding shares of common stock of the Company or the combined voting
power of the Company’s then outstanding securities (not including any securities beneficially owned by such
Person which are or were acquired directly from the Company or its Affiliates).
(iv) 	The Board of Directors adopts a resolution to the effect that, for purposes of this Agreement, a Potential
Change in Control exists; provided that a Potential Change in Control described in this paragraph (iv) shall
cease to exist upon a determination by the Board of Directors that the reasons that gave rise to the resolution
providing for the existence of a Potential Change in Control have expired or no longer exist.
4.8 	The provisions of Sections 4.5, 4.6, 4.7 and this Section 4.8 may not be amended or deleted, nor superseded by any other
provision of this Plan, (i) during the pendency of a Potential Change in Control and (ii) during the period beginning on the date of a Change
in Control and ending on the date five (5) years following such Change in Control.
SECTION 5.
CONVERSION TO COMMON STOCK UNITS
5.1 	Any Director who is then serving as a director may, by written notice filed with the Secretary of the Company, irrevocably
elect to have all or any portion of deferred fees previously earned but not yet paid, transferred from the Director’s Deferred Fee Account to a
stock account established
5

-- 33 of 51 --

under this Section 5 (“Stock Account”). Any election as to a portion of such fees shall be expressed as a percentage and the same percentage
shall be applied to all such fees regardless of the calendar year in which earned or to all deferred fees earned in designated calendar years, as
specified by the Director. A Director may make no more than one notional investment election under this Section 5.l in any calendar year. All
such elections may apply only to deferred fees for which an election has not previously been made and shall be irrevocable.
5.2 	Any Director may, by written notice filed with the Secretary of the Company, elect to have all or any portion of deferred fees
earned subsequent to the date such notice is filed credited to a Stock Account established under this Section 5. Fees covered by such election
shall be credited to such account at the end of each calendar quarter in, or for which, such fees are earned. Such election may be revoked or
modified by such Director, by written notice filed with the Secretary of the Company, as to deferred fees to be earned in calendar years
subsequent to the calendar year such notice is filed, but shall be irrevocable as to deferred fees earned prior to such year.
5.3 	Deferred fees credited to a Stock Account under Section 5.1 shall be converted to Common Stock Units by dividing the
deferred fees so credited by the closing price of common shares of the Company on the date the notice of election under Section 5 is received
by the Company (or the next business day, if there are no sales on such date) as reported on the New York Stock Exchange Composite
Reporting System. Deferred fees credited to a Stock Account under Section 5.2 shall be converted to Common Stock Units by dividing the
deferred fees so credited by the closing price of common shares of the Company as of the last business day of the calendar quarter for which
the credit is made, as reported on the New York Stock Exchange Composite Reporting System.
5.4 	Each Common Stock Unit shall be credited with (or adjusted for) the same cash and stock dividends, stock splits and other
distributions and adjustments as are received by or applicable to one common share of the Company. All cash dividends and other cash
distributions credited to Common Stock Units shall be converted to additional Common Stock Units by dividing each such dividend or
distribution by the closing price of common shares of the Company on the payment date for such dividend or distribution, as reported by the
New York Stock Exchange Composite Reporting System.
5.5 	The value of the Common Stock Units credited each Director shall be paid to the Director in cash on the dates specified in
Section 4.3 (or, if applicable, Section 4.5). The amount of each payment shall be determined by multiplying the Common Stock Units
payable on each date specified in Section 4.3 (or, if applicable, Section 4.5) by the closing price of common shares of the Company on the
day prior to the payment date (or the next preceding business day if there are no sales on such date), as reported by the New York Stock
Exchange Composite Reporting System.
SECTION 6.
MISCELLANEOUS
6.1 	Each Director or former Director entitled to payment of deferred fees hereunder, from time to time may name any person or
persons (who may be named contingently or successively) to whom any deferred Director’s fees earned by him and payable to him are to be
paid in case of his death before he receives any or all of such deferred Director’s fees. Each designation will revoke all prior designations by
the same Director or former Director, shall be in a form prescribed by the Company, and will be effective only when filed by the Director or
former Director in writing with the Secretary of the Company during his lifetime. If a deceased Director or former Director shall have failed
to name a beneficiary in the manner provided above, or if the beneficiary named by a deceased Director or former Director dies before him or
before payment of all the Director’s or former Director’s deferred Directors’ fees, the Company, in its discretion, may direct payment of the
remaining installments required by Section 4.3 to either:
(a) 	any one or more or all of the next of kin (including the surviving spouse) of the Director or former Director, and in
such proportions as the Company determines; or
(b) 	the legal representative or representatives of the estate of the last to die of the Director or former Director and his last
surviving beneficiary.
6

-- 34 of 51 --

The person or persons to whom any deceased Director’s or former Director’s deferred Directors’ fees are payable under this Section will be
referred to as his “beneficiary.”
6.2 	Establishment of the Plan and coverage thereunder of any person shall not be construed to confer any right on the part of
such person to be nominated for reelection to the Board of Directors of the Company, or to be reelected to the Board of Directors.
6.3 	Payment of deferred Directors’ fees will be made only to the person entitled thereto in accordance with the terms of the Plan,
and deferred Directors’ fees are not in any way subject to the debts or other obligations of persons entitled thereto, and may not be
voluntarily or involuntarily sold, transferred or assigned. When a person entitled to a payment under the Plan is under legal disability or, in
the Company’s opinion, is in any way incapacitated so as to be unable to manage his financial affairs, the Company may direct that payment
be made to such person’s legal representative, or to a relative or friend of such person for his benefit. Any payment made in accordance with
the preceding sentence shall be in complete discharge of the Company’s obligation to make such payment under the Plan.
6.4 	Any action required or permitted to be taken by the Company under the terms of the Plan shall be by affirmative vote of a
majority of the members of the Board of Directors then in office.
6.5 	Notwithstanding anything in the Plan to the contrary, any amounts under the Plan that were earned and vested before January
1, 2005 (as determined in accordance with Code Section 409A) with respect to a Director who retired before January 1, 2005
(“Grandfathered Amounts”) shall be subject to the terms and conditions of the Plan as administered and as in effect on December 31, 2004.
Amendments made to the Plan pursuant to this amendment and restatement or otherwise shall not affect the Grandfathered Amounts unless
expressly provided for in the amendment. The terms and conditions applicable to the Grandfathered Amounts are set forth in Exhibit A
attached hereto.
6.6 	To the extent applicable, it is intended that the Plan comply with the provisions of Section 409A of the Code. The Plan will
be administered and interpreted in a manner consistent with this intent, and any provision that would cause the Plan to fail to satisfy Section
409A of the Code will have no force and effect until amended to comply therewith (which amendment may be retroactive to the extent
permitted by Section 409A of the Code). Notwithstanding anything contained herein to the contrary, for all purposes of this Plan, a Director
shall not be deemed to have had a termination of service as a Director until the Director has incurred a separation from service as defined in
Treasury Regulation §1.409A-1(h) and, to the extent required to avoid accelerated taxation and/or tax penalties under Code Section 409A and
applicable guidance issued thereunder, payment of the amounts payable under the Plan that would otherwise be payable during the six-month
period after the date of termination shall instead be paid on the first business day after the expiration of such six-month period, plus interest
thereon, at a rate equal to the rate specified in Section 8.8 (to the extent that such interest is not already provided to the Director under
Section 8.10), from the respective dates on which such amounts would otherwise have been paid until the actual date of payment. In addition,
for purposes of the Plan, each amount to be paid and each installment payment shall be construed as a separate identified payment for
purposes of Section 409A of the Code.
6.7 	Except as expressly provided herein, the provisions of the Plan as they were in effect immediately prior to the January 1,
2013 amendment shall continue to apply to any Director who retired or otherwise terminated service as a Director prior to January 1, 2013.
SECTION 7.
AMENDMENT AND DISCONTINUANCE
While the Company expects to continue the Plan, it must necessarily reserve, and does hereby reserve, the right to amend or
discontinue the Plan at any time; provided, however, that any amendment or discontinuance of the Plan shall be prospective in operation only,
and shall not affect the payment of any deferred Directors’ fees theretofore earned by any Director, or the conditions under which any such
fees are to be paid or forfeited under the Plan. Any discontinuance of the Plan by the Company shall comply with the requirements of Section
409A of the Code.
7

-- 35 of 51 --

SECTION 8.
ALTERNATE PAYMENT OF FEES
8.1 	By written notice filed with the Secretary of the Company prior to each calendar year beginning after December 31, 1988, a
Director may elect to receive all or a portion of his fees earned in the following calendar year in accordance with the provisions of Section 8.
An election under this Section 8.1 shall become irrevocable as of December 31 of the calendar year prior to the year in which such monthly
and meeting fees will be earned (or, in the case of a new Director, on the 30 day following the Director’s first participation in the Plan and
all plans that would be aggregated with the Plan pursuant to Treasury Regulation §1.409A-1(c)(2)(i), provided, that the compensation subject
to such election relates solely to services performed after the date of such election).
8.2 	If payment of a Director’s fees is made pursuant to Section 8.1, such fees shall not be deferred and a portion of the gross
amount of such fees shall be paid currently in cash for the Director directly to a “Grantor Trust” established by the Director, provided such
trust is in a form which the Company determines to be substantially similar to the trust attached to this plan as Exhibit B; and the balance of
the gross amount of such fees shall be paid currently in cash directly to the Director, provided that the portion paid directly to the Director
shall be an amount equal to the aggregate federal, state and local individual income taxes attributable to the gross fees paid pursuant to this
Section 8.2 (determined in accordance with Section 8.14). In no event shall such fees be paid to the Grantor Trust or directly to the Director
later than the last day of the “applicable 2½ month period,” as such term is defined in Treasury Regulation § 1.409A-1(b)(4)(i)(A).
8.3 	The Company will establish and maintain four separate accounts in the name of each Director who has made an election
under Section 8.1 as follows: a “Pre-Tax Fee Account,” an “After-Tax Fee Account,” a “Pre-Tax Stock Account” and an “After-Tax Stock
Account” (collectively, the “Accounts”).
(a) The Pre-Tax Fee Account shall reflect the total amount of any fees paid in cash to a Director or deposited to a Director’s
Grantor Trust, including the amount equal to the aggregate federal, state and local individual income taxes
attributable to the fees paid pursuant to Section 8.2, and Interest to be credited to a Director pursuant to Section 8.8.
The After-Tax Fee Account shall reflect such gross amounts but shall be maintained on an after-tax basis.
(b) The Pre-Tax Stock Account shall reflect the total amount of fees converted to Common Stock Units pursuant to Section
5, including the amount equal to the aggregate federal, state and local individual income taxes attributable to the fees
paid pursuant to Section 8.2, and any adjustments made pursuant to Section 8.9. The After-Tax Stock Account shall
reflect such gross amounts but shall be maintained on an after-tax basis.
(c) The Accounts established pursuant to this Section 8.3 are for the convenience of the administration of the Plan and no
trust relationship with respect to such Accounts is intended or should be implied.
8.4 	As of the end of each calendar year, the Company shall adjust each Director’s Pre-Tax Fee Account as follows:
(a) FIRST, charge, in any year in which the Director is entitled to receive a distribution from his or her Grantor Trust, an
amount equal to the distribution from the fee account maintained thereunder that would have been made to the
th
8

-- 36 of 51 --

Director if the aggregate amounts paid according to Section 8.2 had instead been deferred under Section 3;
(b) NEXT, credit an amount equal to the gross amount of any fees paid for that year, not converted to Common Stock Units,
that are paid to the Director (including the amount deposited in the Director’s Grantor Trust and the amount equal to
the aggregate federal, state and local individual income taxes attributable to the fees paid pursuant to Section 8.2)
according to Section 8.2; and
(c ) FINALLY, credit an amount equal to the Interest earned for that year according to Section 8.8.
8.5 	As of the end of each calendar year, the Company shall adjust each Director’s After-Tax Fee Account as follows:
(a) 	FIRST, charge, in any year in which the Director is in receipt of a benefit distribution from his or her Grantor Trust,
an amount equal to the product of (i) the distribution that would have been made to the Director if the aggregate
amounts paid according to Section 8.2 had instead been deferred under Section 3, multiplied by (ii) a fraction, the
numerator of which is the balance in the Director’s After-Tax Fee Account as of the end of the prior fiscal year and
the denominator of which is the balance of the Director’s Pre-Tax Fee Account as of that same date;
(b) 	NEXT, credit an amount equal to the fees not converted to Common Stock Units that are paid that year to the
Director directly to the Director’s Grantor Trust according to Section 8.2; and
(c) 	FINALLY, credit an amount equal to the After-Tax Interest earned for that year according to Section 8.8.
8.6 	As of the end of each calendar year, the Company shall adjust each Director’s Pre-Tax Stock Account as follows:
(a) FIRST, charge, in any year in which the Director is entitled to receive a distribution from his or her Grantor Trust, an
amount equal to the distribution that would have been made to the Director if the aggregate amount of fees paid
according to Section 8.2 had instead been deferred under Section 3 and the adjustments had been made under
Section 5;
(b) NEXT, credit an amount equal to the total amount of any fees for that year that are converted to Common Stock Units
and paid to the Director (including the amount deposited in the Director’s Grantor Trust and the amount equal to the
aggregate federal, state and local individual income taxes attributable to the fees paid pursuant to Section 8.2) and
allocated to the Stock Account maintained thereunder) according to Section 8.2; and
(c) NEXT, credit an amount equal to the net earnings of the Director’s Grantor Trust for the year; and
(d) FINALLY, credit an amount equal to the Book Value Adjustments to be made for that year according to Section 8.9.
9

-- 37 of 51 --

8.7 	As of the end of each calendar year, the Company shall adjust each Director’s After-Tax Stock Account as follows:
(a) 	FIRST, charge, in any year in which the Director is entitled to receive a distribution from his or her Grantor Trust, an
amount equal to the product of (i) the distribution that would have been made to the Director if the aggregate
amounts paid according to Section 8.2 had instead been deferred under Section 3 and the adjustments had been made
under Section 5, multiplied by (ii) a fraction, the numerator of which is the balance in the Director’s After-Tax Stock
Account as of the end of the prior fiscal year and the denominator of which is the balance of the Director’s Pre-Tax
Stock Account as of that same date;
(b) 	NEXT, credit an amount equal to the fees converted to Common Stock Units that are paid that year to the Director
directly to the Director’s Grantor Trust and allocated to the Stock Account maintained thereunder according to
Section 8.2; and
(c) 	NEXT, credit an amount equal to the net earnings of the Director’s Grantor Trust for the year; and
(d) 	FINALLY, credit an amount equal to the Book Value Adjustments to be made for that year according to Section 8.9.
8.8 	The Director’s Pre-Tax Fee Account and After-Tax Fee Account shall be credited with interest as follows:
(a) 	As of the end of each calendar year, a Director’s Pre-Tax Fee Account shall be credited with interest (“Interest”) at
the following rate:
(i) 	the average of the “prime rate” of interest published by the Wall Street Journal (Mid-West Edition) or
comparable successor quotation service on the first business day of January and the last business day of each
month of the fiscal year;
(ii) 	plus two hundred twenty-five (225) basis points.
(b) 	As of the end of each calendar year, a Director’s After-Tax Fee Account shall be credited with the amount of Interest
set forth above, multiplied by (one minus the aggregate of the applicable federal, state and local individual income
tax rates and employment tax rate, determined in accordance with subsection 7.5) (the “After-Tax Interest”).
8.9 	As of the end of each calendar year, a Director’s Pre-Tax Stock Account and After-Tax Stock Account shall be adjusted as
provided in Section 5.4, to the extent applicable, and shall also be adjusted to reflect the increase or decrease in the fair market value of the
Company’s common stock determined in accordance with Section 5.5, except that (i) any reference to the payment date in such Section shall
mean December 31 of the applicable calendar year for purposes of this Section, and (ii) adjustments to the After-Tax Stock Account shall be
made on an after-tax basis. Such adjustments shall be referred to as “Book Value Adjustments.”
8.10 	In addition to any fees paid to a Director’s Grantor Trust under Section 8.2 during the year, the Company shall also make a
payment (an “Interest Payment”) with respect to each Director who has established a Grantor Trust for each year in which the Grantor Trust
is in effect. The Interest Payment shall equal the excess, if any, of the gross amount of the Interest credited to the Director (as defined in
Section 8.8(a)), over the net earnings of the Director’s Grantor Trust for the year, and shall be paid within thirty (30) days beginning April 1
of the following calendar year. A portion of such gross Interest Payment, equal to the excess, if any, of the Net Interest Accrual over the net
earnings of the Director’s Grantor Trust (i.e., the Pre-Amendment Amount), shall be deposited in the Director’s Grantor
10

-- 38 of 51 --

Trust, with the balance paid to the Director; provided, however, in the event that the net earnings of the Director’s Grantor Trust exceeds the
Net Interest Accrual, a distribution from the Grantor Trust shall be required in accordance with Section 8.15. A Director’s Net Interest
Accrual for a year is an amount equal to the After-Tax Interest credited to the Director’s After-Tax Fee Account for that year in accordance
with Section 8.8(b).
8.11 	In addition to the fees paid under Section 8.2 during the year and the Interest Payment described above, the Company shall
also make a payment (a “Principal Payment”) with respect to each Director who has established a Grantor Trust for each year in which the
Grantor Trust is in effect, to be credited to the Stock Account maintained thereunder. Prior to January 1, 2013, the Principal Payment equaled
the excess, if any, of 75 percent of the fair market value (as determined in accordance with Section 5.5) of the balance of the Director’s After-
Tax Stock Account on December 31 over the balance in the Stock Account maintained under the Director’s Grantor Trust as of that same
date, and was paid within the thirty (30)-day period beginning April 1 of the following calendar year. Effective as of January 1, 2013, the
Principal Payment shall equal the excess, if any, of 75 percent of the fair market value (as determined in accordance with Section 5.5) of the
balance of the Director’s Pre-Tax Stock Account on December 31 over the balance in the Stock Account maintained under the Director’s
Grantor Trust as of that same date, and shall be paid within the thirty (30)-day period beginning April 1 of the following calendar year. For
the calendar year in which the last installment distribution is made from the Director’s Grantor Trust (meaning, the year that is X years
following the year of the event triggering the payments, where X is the same number of years served by the Director), the payment made
under this Section 8.11 shall equal the excess, if any, of 100 percent of the balance of the Director’s After-Tax Stock Account over the
balance in the Stock Account maintained under the Director’s Grantor Trust as of that same date.
8.12 	Each Director’s Grantor Trust assets shall be invested solely in the instruments specified by investment guidelines
established by the Committee. Such investment guidelines, once established, may be changed by the Committee, provided that any change
shall not take effect until the year following the year in which the change is made and provided further that the instruments specified shall be
consistent with the provisions of Section 3(b) of the form of Grantor Trust attached hereto as Exhibit B.
8.13 	For purposes of Section 8, a Director’s federal income tax rate shall be deemed to be the highest marginal rate of federal
individual income tax in effect in the calendar year in which a calculation under this Section is to be made and state and local tax rates shall
be deemed to be the highest marginal rates of individual income tax in effect in the state and locality of the Director’s residence on the date
such a calculation is made, net of any federal tax benefits without a benefit for any net capital losses. Notwithstanding the preceding
sentence, if a Director is not a citizen or resident of the United States, his or her income tax rates shall be deemed to be the highest marginal
income tax rates actually imposed on the Director’s benefits under this Plan or earnings under his or her Grantor Trust without a benefit for
any net capital losses.
8.14 	If a portion of a Director’s fees have been paid to a Grantor Trust pursuant to Section 8.2, then those fees and earnings
thereon shall be paid to him or her from the Grantor Trust in the order in which they were earned (i.e., the fees for the earliest year of service
as a Director will be the first fees distributed from the Grantor Trust(s), the fees for the next earliest year of service as a Director will be paid
on the anniversary of the payment of the first installment, etc.) The distribution of a Director’s fees shall continue until all fees to which the
Director is entitled to receive under the Plan shall have been paid in accordance with the terms of the Grantor Trust(s).
8.15 	Abbott, as the administrator of the Director’s Grantor Trust, may direct the trustee to distribute to the Director from the
income of such Grantor Trust, a sum of money sufficient to pay the taxes on trust earnings for such year, to the extent a sufficient sum of
money has not been paid to the Director pursuant to Section 8.10 or 8.11, as applicable. The taxes shall be determined in accordance with
Section 8.13.
8.16 	Abbott, as the administrator of the Director’s Grantor Trust, may direct the trustee to pay the appropriate federal, state and
local individual income taxes attributable to the fees and other payments paid to the Director pursuant to Sections 8.2, 8.10 and 8.11 to the
applicable tax authorities on behalf of the Director. The taxes shall be determined in accordance with Section 8.13.
11

-- 39 of 51 --

Exhibit A
ABBOTT LABORATORIES NON-EMPLOYEE DIRECTORS’ FEE PLAN
[Abbott Laboratories Non-Employee Directors’ Fee Plan, as amended, as filed as Exhibit 10.1 to the Abbott Laboratories Current Report
on Form 8-K dated February 17, 2006.]

-- 40 of 51 --

Exhibit B
IRREVOCABLE GRANTOR TRUST AGREEMENT
THIS AGREEMENT, made this ______ day of ______________, 20___, by and between 	of 	, 	(the
“grantor”), and The Northern Trust Company located at Chicago, Illinois, as trustee (the “trustee”),
WITNESSETH THAT:
WHEREAS, the grantor desires to establish and maintain a trust to hold certain benefits received by the grantor under the Abbott
Laboratories Non-Employee Directors’ Fee Plan, as it may be amended from time to time;
NOW, THEREFORE, it is agreed as follows:
ARTICLE I
Introduction
I-1. 	Name. This agreement and the trust hereby evidenced (the “trust”) may be referred to as the “ 	Grantor Trust.”
I-2. 	The Trust Fund. The “trust fund” as at any date means all property then held by the trustee under this agreement.
I-3. 	Status of the Trust. The trust shall be irrevocable. The trust is intended to constitute a grantor trust under Sections 671-678 of
the Internal Revenue Code, as amended, and shall be construed accordingly.
I-4. 	The Administrator. Abbott Laboratories (“Abbott”) shall act as the “administrator” of the trust, and as such shall have certain
powers, rights and duties under this agreement as described below. Abbott will certify to the trustee from time to time the person or persons
authorized to act on behalf of Abbott as the administrator. The trustee may rely on the latest certificate received without further inquiry or
verification.
I-5. 	Acceptance. The trustee accepts the duties and obligations of the “trustee” hereunder, agrees to accept funds delivered to it
by the grantor or the administrator, and agrees to hold such funds (and any proceeds from the investment of such funds) in trust in accordance
with this agreement.

-- 41 of 51 --

ARTICLE II
Distribution of the Trust Fund
II-1. 	Separate Accounts. The administrator shall maintain two separate accounts under the trust, a “deferred account” and a “stock
account.” Funds delivered to the trustee shall be allocated between the accounts by the trustee as directed by the administrator. As of the end
of each calendar year, the administrator shall charge each account with all distributions made from such account during that year; and credit
each account with its share of income and realized gains and charge each account with its share of expenses and realized losses for the year.
The trustee shall be required to make separate investments of the trust fund for the accounts, and may not administer and invest all funds
delivered to it under the trust as one trust fund.
II-2. 	Distributions Prior to the Grantor’s Death. Principal and accumulated income shall not be distributed from the trust prior to
the grantor’s termination of service as a Director of Abbott (the grantor’s “settlement date”); provided that, each year the administrator may
direct the trustee to distribute to the grantor a portion of the income of the trust fund for that year, with the balance of such income to be
accumulated in the trust. The administrator shall inform the trustee of the grantor’s settlement date. Thereafter, the trustee shall distribute the
trust fund to the grantor, if then living, in a series of annual installments, commencing on the first day of the month next following the later of
the grantor’s settlement date or the date the grantor attains age 65 years. The administrator shall inform the trustee of the number of
installment distributions and the amount of each installment distribution under this paragraph II-2, and the trustee shall be fully protected in
relying on such information received from the administrator.
II-3. 	Distributions After the Grantor’s Death. The grantor, from time to time may name any person or persons (who may be named
contingently or successively and who may be natural persons or fiduciaries) to whom the principal of the trust fund and all accrued or
undistributed income thereof shall be distributed in a lump sum or, if the beneficiary is the grantor’s spouse (or a trust for which the grantor’s
spouse is the sole income beneficiary), in installments, as directed by the grantor, upon the grantor’s death. If the grantor directs an
installment method of distribution to the spouse as beneficiary, any amounts remaining at the death of the spouse beneficiary shall be
distributed in a lump sum to the executor or administrator of the spouse beneficiary’s estate. If the grantor directs an installment method of
distribution to a trust for which the grantor’s spouse is the sole income beneficiary, any amounts remaining at the death of the spouse shall be
distributed in a lump sum to such trust. Despite the foregoing, if (i) the beneficiary is a trust for which the grantor’s spouse is the sole income
beneficiary, (ii) payments are being made pursuant to this paragraph II-3 other than in a lump sum and (iii) income earned by the trust fund
for the year exceeds the amount of the annual installment payment, then such trust may elect to withdraw such excess income by written
notice to the trustee. Each designation shall revoke all prior designations, shall be in writing and shall be effective only when filed by the
grantor with the administrator during the grantor’s lifetime. If the grantor fails to direct a method of distribution, the distribution shall be
made in a lump sum. If the grantor fails to designate a beneficiary as provided above, then on the grantor’s death, the trustee shall distribute
the balance of the trust fund in a lump sum to the executor or administrator of the grantor’s estate.
II-4. 	Facility of Payment. When a person entitled to a distribution hereunder is under legal disability, or, in the trustee’s opinion, is
in any way incapacitated so as to be unable to manage his or her financial affairs, the trustee may make such distribution to such person’s
legal representative, or to a relative or friend of such person for such person’s benefit. Any distribution made in accordance with the
preceding sentence shall be a full and complete discharge of any liability for such distribution hereunder.
2

-- 42 of 51 --

II-5. 	Perpetuities. Notwithstanding any other provisions of this agreement, on the day next preceding the end of 21 years after the
death of the last to die of the grantor and the grantor’s descendants living on the date of this instrument, the trustee shall immediately
distribute any remaining balance in the trust to the beneficiaries then entitled to distributions hereunder.
ARTICLE III
Management of the Trust Fund
III-1. General Powers. The trustee shall, with respect to the trust fund, have the following powers, rights and duties in addition to
those provided elsewhere in this agreement or by law:
(a) 	Subject to the limitations of subparagraph (b) next below, to sell, contract to sell, purchase, grant or exercise options to
purchase, and otherwise deal with all assets of the trust fund, in such way, for such considerations, and on such terms and
conditions as the trustee decides.
(b) 	To retain in cash such amounts as the trustee considers advisable; and to invest and reinvest the balance of the trust fund,
without distinction between principal and income, in common stock of Abbott Laboratories, or in obligations of the United
States Government and its agencies or which are backed by the full faith and credit of the United States Government or in
any mutual fund, common trust fund or collective investment fund which invests solely in such obligations; and any such
investment made or retained by the trustee in good faith shall be proper despite any resulting risk or lack of diversification or
marketability.
(c) 	To deposit cash in any depositary (including the banking department of the bank acting as trustee) without liability for
interest, and to invest cash in savings accounts or time certificates of deposit bearing a reasonable rate of interest in any such
depositary.
(d) 	To invest, subject to the limitations of subparagraph (b) above, in any common or commingled trust fund or funds
maintained or administered by the trustee solely for the investment of trust funds.
(e) 	To borrow from anyone, with the administrator’s approval, such sum or sums from time to time as the trustee considers
desirable to carry out this trust, and to mortgage or pledge all or part of the trust fund as security.
(f) 	To retain any funds or property subject to any dispute without liability for interest and to decline to make payment or
delivery thereof until final adjudication by a court of competent jurisdiction or until an appropriate release is obtained.
(g) 	To begin, maintain or defend any litigation necessary in connection with the administration of this trust, except that the
trustee shall not be obliged or required to do so unless indemnified to the trustee’s satisfaction.
(h) 	To compromise, contest, settle or abandon claims or demands.
3

-- 43 of 51 --

(i) 	To give proxies to vote stocks and other voting securities, to join in or oppose (alone or jointly with others) voting trusts,
mergers, consolidations, foreclosures, reorganizations, liquidations, or other changes in the financial structure of any
corporation, and to exercise or sell stock subscription or conversion rights.
(j) 	To hold securities or other property in the name of a nominee, in a depositary, or in any other way, with or without disclosing
the trust relationship.
(k) 	To divide or distribute the trust fund in undivided interests or wholly or partly in kind.
(l) 	To pay any tax imposed on or with respect to the trust; to defer making payment of any such tax if it is indemnified to its
satisfaction in the premises; and to require before making any payment such release or other document from any lawful
taxing authority and such indemnity from the intended payee as the trustee considers necessary for its protection.
(m) 	To deal without restriction with the legal representative of the grantor’s estate or the trustee or other legal representative of
any trust created by the grantor or a trust or estate in which a beneficiary has an interest, even though the trustee,
individually, shall be acting in such other capacity, without liability for any loss that may result.
(n) 	To appoint or remove by written instrument any bank or corporation qualified to act as successor trustee, wherever located,
as special trustee as to part or all of the trust fund, including property as to which the trustee does not act, and such special
trustee, except as specifically limited or provided by this or the appointing instrument, shall have all of the rights, titles,
powers, duties, discretions and immunities of the trustee, without liability for any action taken or omitted to be taken under
this or the appointing instrument.
(o) 	To appoint or remove by written instrument any bank, wherever located, as custodian of part or all of the trust fund, and each
such custodian shall have such rights, powers, duties and discretions as are delegated to it by the trustee.
(p) 	To employ agents, attorneys, accountants or other persons, and to delegate to them such powers as the trustee considers
desirable, and the trustee shall be protected in acting or refraining from acting on the advice of persons so employed without
court action.
(q) 	To perform any and all other acts which in the trustee’s judgment are appropriate for the proper management, investment and
distribution of the trust fund.
III-2. Principal and Income. Any income earned on the trust fund, which is not distributed as provided in Article II shall be
accumulated and from time to time added to the principal of the trust. The grantor’s interest in the trust shall include all assets or other
property held by the trustee hereunder, including principal and accumulated income.
III-3. Statements. The trustee shall prepare and deliver monthly to the administrator and annually to the grantor, if then living,
otherwise to each beneficiary then entitled to distributions under
4

-- 44 of 51 --

this agreement, a statement (or series of statements) setting forth (or which taken together set forth) all investments, receipts, disbursements
and other transactions effected by the trustee during the reporting period; and showing the trust fund and the value thereof at the end of such
period.
III-4. Compensation and Expenses. All reasonable costs, charges and expenses incurred in the administration of this trust,
including compensation to the trustee, any compensation to agents, attorneys, accountants and other persons employed by the trustee, and
expenses incurred in connection with the sale, investment and reinvestment of the trust fund shall be paid from the trust fund.
ARTICLE IV
General Provisions
IV-1. Interests Not Transferable. The interests of the grantor or other persons entitled to distributions hereunder are not subject to
their debts or other obligations and may not be voluntarily or involuntarily sold, transferred, alienated, assigned or encumbered.
IV-2. Disagreement as to Acts. If there is a disagreement between the trustee and anyone as to any act or transaction reported in
any accounting, the trustee shall have the right to a settlement of its account by any proper court.
IV-3. Trustee’s Obligations. No power, duty or responsibility is imposed on the trustee except as set forth in this agreement. The
trustee is not obliged to determine whether funds delivered to or distributions from the trust are proper under the trust, or whether any tax is
due or payable as a result of any such delivery or distribution. The trustee shall be protected in making any distribution from the trust as
directed pursuant to Article II without inquiring as to whether the distributee is entitled thereto; and the trustee shall not be liable for any
distribution made in good faith without written notice or knowledge that the distribution is not proper under the terms of this agreement.
IV-4. Good Faith Actions. The trustee’s exercise or non-exercise of its powers and discretions in good faith shall be conclusive on
all persons. No one shall be obliged to see to the application of any money paid or property delivered to the trustee. The certificate of the
trustee that it is acting according to this agreement will fully protect all persons dealing with the trustee.
IV-5. Waiver of Notice. Any notice required under this agreement may be waived by the person entitled to such notice.
IV-6. Controlling Law. The laws of the State of Illinois shall govern the interpretation and validity of the provisions of this
agreement and all questions relating to the management, administration, investment and distribution of the trust hereby created.
IV-7. Successors. This agreement shall be binding on all persons entitled to distributions hereunder and their respective heirs and
legal representatives, and on the trustee and its successors.
5

-- 45 of 51 --

ARTICLE V
Changes in Trustee
V-1. Resignation or Removal of Trustee. The trustee may resign at any time by giving thirty days’ advance written notice to the
administrator and the grantor. The administrator may remove a trustee by written notice to the trustee and the grantor.
V-2. Appointment of Successor Trustee. The administrator shall fill any vacancy in the office of trustee as soon as practicable by
written notice to the successor trustee; and shall give prompt written notice thereof to the grantor, if then living, otherwise to each beneficiary
then entitled to payments or distributions under this agreement. A successor trustee shall be a bank (as defined in Section 581 of the Internal
Revenue Code, as amended).
V-3. Duties of Resigning or Removed Trustee and of Successor Trustee. A trustee that resigns or is removed shall furnish
promptly to the administrator and the successor trustee an account of its administration of the trust from the date of its last account. Each
successor trustee shall succeed to the title to the trust fund vested in its predecessor without the signing or filing of any instrument, but each
predecessor trustee shall execute all documents and do all acts necessary to vest such title of record in the successor trustee. Each successor
trustee shall have all the powers conferred by this agreement as if originally named trustee. No successor trustee shall be personally liable for
any act or failure to act of a predecessor trustee. With the approval of the administrator, a successor trustee may accept the account furnished
and the property delivered by a predecessor trustee without incurring any liability for so doing, and such acceptance will be complete
discharge to the predecessor trustee.
ARTICLE VI
Amendment and Termination
VI-1. Amendment. With the consent of the administrator, this trust may be amended from time to time by the grantor, if then
living, otherwise by a majority of the beneficiaries then entitled to payments or distributions hereunder, except as follows:
(a) 	The duties and liabilities of the trustee cannot be changed substantially without its consent.
(b) 	This trust may not be amended so as to make the trust revocable.
VI-2. Termination. This trust shall not terminate, and all rights, titles, powers, duties, discretions and immunities imposed on or
reserved to the trustee, the administrator, the grantor and the beneficiaries shall continue in effect, until all assets of the trust have been
distributed by the trustee as provided in Article II.
* 	* 	*
6

-- 46 of 51 --

IN WITNESS WHEREOF, the grantor has executed this Agreement as of the day and year first above written.
___________________________________
Grantor
The Northern Trust Company as Trustee
By______________________________
Its______________________________
7

-- 47 of 51 --

Exhibit 31.1
Certification of Chief Executive Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Robert B. Ford, certify that:
1. 	I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
4. 	Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for
Abbott and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal
quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and
5. 	Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s
auditors and the audit committee of Abbott’s board of directors:
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control
over financial reporting.
Date: April 30, 2025 	/s/ ROBERT B. FORD
Robert B. Ford
Chairman of the Board and Chief Executive Officer

-- 48 of 51 --

Exhibit 31.2
Certification of Chief Financial Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Philip P. Boudreau, certify that:
1. 	I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
4. 	Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for
Abbott and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal
quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and
5. 	Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s
auditors and the audit committee of Abbott’s board of directors:
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control
over financial reporting.
Date: April 30, 2025 	/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Executive Vice President, Finance
and Chief Financial Officer

-- 49 of 51 --

Exhibit 32.1
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended March 31, 2025 as filed with
the Securities and Exchange Commission (the “Report”), I, Robert B. Ford, Chairman of the Board and Chief Executive Officer of the Company, certify,
pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ ROBERT B. FORD
Robert B. Ford
Chairman of the Board and Chief Executive Officer
April 30, 2025
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories
and furnished to the Securities and Exchange Commission or its staff upon request.

-- 50 of 51 --

Exhibit 32.2
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended March 31, 2025 as filed with
the Securities and Exchange Commission (the “Report”), I, Philip B. Boudreau, Executive Vice President, Finance and Chief Financial Officer of the
Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Executive Vice President, Finance
and Chief Financial Officer
April 30, 2025
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories
and furnished to the Securities and Exchange Commission or its staff upon request.

-- 51 of 51 --